News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
590,167 Results
Type
Article (19601)
Company Profile (185)
Press Release (570379)
Multimedia
Podcasts (84)
Webinars (13)
Section
Business (199086)
Career Advice (720)
Deals (30883)
Drug Delivery (108)
Drug Development (66005)
Employer Resources (55)
FDA (12476)
Job Trends (11196)
News (288928)
Policy (24232)
Tag
2025 Best Places to Work (9)
2026 Best Places to Work (17)
2027 BioCapital Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (6)
2027 Biotech Beach Digital (1)
2027 Biotech Beach Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (1)
40 Under 40 (2)
Academia (872)
Accelerated approval (53)
ADA (26)
Adcomms (10)
Allergies (160)
Alliances (41953)
ALS (170)
Alzheimer's disease (1347)
Antibody-drug conjugate (ADC) (450)
Approvals (13256)
Artificial intelligence (616)
ASCO (221)
Autoimmune disease (334)
Automation (48)
Bankruptcy (322)
Belgium (9)
Best Places to Work (8435)
BIO (50)
Biologics (89)
BIOSECURE Act (10)
Biosimilars (222)
BioSpace Insights (86)
Biotechnology (106)
Bispecific (32)
Bladder cancer (168)
Brain cancer (68)
Breast cancer (669)
Cancer (5141)
Cardiovascular disease (416)
Career advice (630)
Career pathing (17)
CAR-T (251)
CDC (12)
CDMO (120)
Celiac Disease (4)
Cell therapy (696)
Cervical cancer (48)
Clinical research (60099)
Collaboration (1937)
Commercialization (54)
Company closure (3)
Compensation (1696)
Complete response letters (65)
COVID-19 (1331)
CRISPR (96)
CRO (3)
C-suite (1263)
Cystic fibrosis (132)
Data (8009)
Decentralized trials (2)
Denatured (24)
Depression (137)
Dermatology (129)
Diabetes (511)
Diagnostics (4985)
Digital health (53)
Diversity (3)
Diversity, equity & inclusion (16)
Drug discovery (313)
Drug pricing (130)
Drug shortages (16)
Duchenne muscular dystrophy (256)
Earnings (82520)
Editorial (26)
Employer branding (5)
Employer resources (51)
ESMO (279)
Events (101520)
Executive appointments (1041)
Eye disease (10)
FDA (16118)
Fibrodysplasia Ossificans Progressiva (13)
Fragile X (4)
Friedreich's ataxia (24)
Frontotemporal dementia (32)
Funding (1398)
Gene editing (183)
Generative AI (44)
Gene therapy (526)
GLP-1 (738)
Government (2065)
Grass and pollen (5)
Guidances (339)
Healthcare (11266)
Hematology (150)
HIV (64)
Huntington's disease (40)
Idiopathic pulmonary fibrosis (8)
IgA nephropathy (123)
Immunology and inflammation (192)
Immuno-oncology (101)
Indications (241)
Infectious disease (1594)
Inflammatory bowel disease (195)
Inflation Reduction Act (9)
Influenza (105)
Intellectual property (329)
Interviews (94)
IPO (14038)
IRA (33)
Job creations (3116)
Job search strategy (564)
JPM (30)
Kidney cancer (24)
Kidney disease (125)
Labor market (48)
Layoffs (268)
Leadership (16)
Legal (6596)
Licensing (103)
Liver cancer (58)
Longevity (39)
Lung cancer (741)
Lung diease (13)
Lymphoma (386)
Machine learning (39)
Management (19)
Manufacturing (1107)
Marketing (36)
MASH (185)
Medical affairs (4)
Medical device (9423)
Medtech (9639)
Mergers & acquisitions (18162)
Metabolic disorders (1222)
Middle East (1)
mRNA (152)
Multiple sclerosis (160)
Multispecific (5)
NASH (15)
Netherlands (11)
Neurodegenerative disease (348)
Neuropsychiatric disorders (79)
Neuroscience (2706)
Neurotech (3)
NextGen: Class of 2026 (3936)
Non-profit (1289)
Now hiring (29)
Obesity (490)
Opinion (171)
Ovarian cancer (210)
Pain (281)
Pancreatic cancer (274)
Parkinson's disease (309)
Partnered (26)
Patents (657)
Patient advocacy (4)
Patient recruitment (661)
Patient selection (71)
Peanut (43)
People (51376)
Peptides (33)
Pharmaceutical (47)
Pharmacy benefit managers (26)
Phase 1 (18488)
Phase 2 (26469)
Phase 3 (19671)
Pipeline (11096)
Policy (182)
Postmarket research (2140)
Preclinical (7666)
Press Release (49)
Prostate cancer (264)
Psychedelics (43)
Radioligand (1)
Radiopharmaceuticals (299)
Rare diseases (981)
Real estate (4488)
Recruiting (20)
Regenerative medicine (21)
Regulatory (20436)
Reports (36)
Research institute (995)
Resumes & cover letters (97)
Rett syndrome (51)
RNA editing (17)
RSV (57)
Saudi Arabia (1)
Schizophrenia (167)
Series A (261)
Series B (170)
Service/supplier (5)
Sickle cell disease (108)
Special edition (16)
Spinal muscular atrophy (120)
Sponsored (17)
Startups (2808)
State (2)
Stem cells (4)
Stomach cancer (10)
Substance use disorders (18)
Supply chain (107)
Switzerland (13)
Tariffs (75)
The Weekly (58)
Vaccines (596)
Venture capital (73)
Weight loss (258)
Wet AMD (3)
Women's health (129)
Worklife (6)
Date
Today (169)
Last 7 days (693)
Last 30 days (2932)
Last 365 days (23657)
2026 (21506)
2025 (23430)
2024 (27364)
2023 (31553)
2022 (40959)
2021 (43545)
2020 (40087)
2019 (29951)
2018 (22790)
2017 (24785)
2016 (23654)
2015 (29547)
2014 (25735)
2013 (22113)
2012 (24139)
2011 (24486)
2010 (23716)
Location
Africa (483)
Alabama (90)
Alaska (2)
Arizona (371)
Arkansas (14)
Asia (30656)
Australia (4233)
California (14257)
Canada (3831)
China (1213)
Colorado (590)
Connecticut (539)
Delaware (314)
Europe (56378)
Florida (2165)
Georgia (458)
Hawaii (3)
Idaho (51)
Illinois (981)
India (126)
Indiana (621)
Iowa (21)
Japan (661)
Kansas (124)
Kentucky (42)
Louisiana (35)
Maine (29)
Maryland (1515)
Massachusetts (9791)
Michigan (346)
Minnesota (675)
Mississippi (6)
Missouri (110)
Montana (27)
Nebraska (17)
Nevada (146)
New Hampshire (69)
New Jersey (3628)
New Mexico (18)
New York (3477)
North Carolina (1687)
North Dakota (4)
Northern California (7244)
Ohio (344)
Oklahoma (18)
Oregon (31)
Pennsylvania (2687)
Puerto Rico (31)
Rhode Island (39)
South America (747)
South Carolina (87)
South Dakota (1)
Southern California (5918)
Tennessee (163)
Texas (2333)
United States (48152)
Utah (437)
Vermont (1)
Virginia (299)
Washington D.C. (53)
Washington State (1096)
West Virginia (2)
Wisconsin (125)
Wyoming (2)
590,167 Results for "horizon pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cardiovascular disease
Novartis’ cholesterol-lowering medicine fails Phase 3, clouding Lp(a) horizons
The failure of Novartis’ pelacarsen to translate its Lp(a)-lowering effects to clinical benefits “marks a meaningful setback” for other companies taking a similar approach to cardiovascular risk, analysts say—including Eli Lilly and Amgen.
September 8, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Horizon Europe-funded HERMOD project launches to support Phase 2 development of HER-096 in Parkinson’s disease
November 11, 2026
·
7 min read
autoimmune disease
Amgen asset from $27.8B Horizon buy scores in Phase 3 Sjögren’s study
Amgen is awaiting another Phase 3 readout for the investigational Sjögren’s disease therapy, set for later this year. William Blair anticipates that at least two trials will be needed to support an FDA application.
September 23, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Omnix Medical Launches New Horizon Europe PEPTAMR Infectious Disease Consortium
- EUR ~8M grant supports the late-stage clinical development of Omnix’s antimicrobial OMN6 - Leading European partners join forces to advance OMN6 for the treatment of life-threatening hospital-acquired infections
July 13, 2026
·
1 min read
Press Releases
Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)
June 29, 2026
·
14 min read
Press Releases
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
September 6, 2026
·
5 min read
Cardiovascular disease
Details from Novartis’ failed cardiovascular trial offer ‘little silver lining’ for rivals
Full data from the Phase 3 HORIZON trial of Novartis’ pelacarsen failed to show any apparent benefit, leading analysts to further reduce the odds of success for Lp(a)-lowering competitors such as Amgen’s olpasiran.
November 9, 2026
·
4 min read
·
Heather McKenzie
Press Releases
Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
September 6, 2026
·
8 min read
Pipeline
Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms
Jefferies expects Moderna to have around seven commercial products in the coming years which, along with a projected 10% revenue growth, could help the company break even in 2028.
June 26, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures
April 7, 2026
·
6 min read
1 of 59,017
Next